Sandbox R.Nithin 6XWD: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Racha Nithin (talk | contribs) No edit summary |
Racha Nithin (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
= SARS-CoV-2 Main Protease (Mpro) – Structure and Covalent Inhibition (PDB: 6XWD) = | <scene name='10/1096858/Overview/1'>= SARS-CoV-2 Main Protease (Mpro) – Structure and Covalent Inhibition (PDB: 6XWD) = | ||
This page provides structural overview of the SARS-CoV-2 main protease (Mpro), | This page provides structural overview of the SARS-CoV-2 main protease (Mpro), | ||
based on the iScience 2020 study (DOI: https://doi.org/10.1016/j.isci.2020.101258) and the | based on the iScience 2020 study (DOI: https://doi.org/10.1016/j.isci.2020.101258) and the | ||
| Line 5: | Line 5: | ||
In this study , the researchers produced SARS-CoV-2 Nsp9 in the lab and sloved its X-ray crystal structure | In this study , the researchers produced SARS-CoV-2 Nsp9 in the lab and sloved its X-ray crystal structure | ||
<scene name='10/1096858/Overview/1'>Text To Be Displayed</scene> | |||
== Introduction == | == Introduction == | ||
| Line 138: | Line 138: | ||
.Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216. Nature Microbiology, 2024. PMCID: PMC10994847 | .Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216. Nature Microbiology, 2024. PMCID: PMC10994847 | ||
. Recent Advances in SARS-CoV-2 Main Protease Inhibitors. Review 2023 — summarizing structural and inhibitor design progress. | . Recent Advances in SARS-CoV-2 Main Protease Inhibitors. Review 2023 — summarizing structural and inhibitor design progress. | ||
</scene> | |||
